Baclofen is a synthetic pharmaceutical compound belonging to the class of centrally acting skeletal muscle relaxants. It is primarily used in the management of spasticity, a condition characterized by increased muscle tone, stiffness and involuntary muscle contractions. Baclofen is an important active pharmaceutical ingredient (API) used in the development of oral and other approved pharmaceutical formulations.
Baclofen acts mainly on gamma-aminobutyric acid type B (GABA-B) receptors in the central nervous system. By activating these receptors, it helps reduce the release of excitatory neurotransmitters and decreases the excessive nerve signals responsible for increased muscle activity.
It is commonly associated with the management of spasticity resulting from conditions such as multiple sclerosis, spinal cord injuries and other neurological disorders. Its muscle-relaxing activity helps reduce muscle stiffness, spasms and associated discomfort.
Baclofen is also used in pharmaceutical research involving GABA-B receptor activity, neuronal signalling and the development of medicines for conditions associated with abnormal muscle tone.
Baclofen has the molecular formula C₁₀H₁₂ClNO₂, a molecular weight of approximately 213.66 g/mol, and CAS number 1134-47-0.
Chemically, Baclofen is a chlorinated derivative of gamma-aminobutyric acid (GABA). Its structure contains an amino group, a carboxylic acid group and a chlorine-substituted phenyl ring. These structural features contribute to its pharmacological activity and interaction with GABA-B receptors.
Baclofen is also known by the chemical name 4-amino-3-(4-chlorophenyl)butanoic acid. It is a racemic compound containing two enantiomeric forms, although the marketed medicinal substance is generally the racemate unless a specific enantiomer is expressly identified.
Chemical identity details:
Baclofen acts primarily as an agonist at GABA-B receptors, which are metabotropic receptors found throughout the central nervous system. These receptors play an important role in regulating neuronal excitability and controlling the transmission of nerve signals.
When Baclofen activates GABA-B receptors, it reduces excitatory neurotransmitter release and decreases neuronal activity in pathways involved in muscle reflexes. This helps reduce excessive reflex responses and involuntary muscle contractions.
The general mechanism can be understood through the following steps:
This mechanism makes Baclofen different from muscle relaxants that act primarily through direct effects on skeletal muscle. Its principal action occurs through inhibitory neurotransmission in the central nervous system.
Baclofen is primarily used in pharmaceutical formulations intended for the management of spasticity and certain neurological conditions associated with increased muscle tone.
Spasticity can develop when the normal communication between the brain, spinal cord and muscles is disrupted. It may cause stiffness, painful spasms, restricted movement and difficulties with everyday activities. Baclofen helps manage these symptoms by reducing excessive neuronal activity involved in muscle reflexes.
Its pharmaceutical applications include:
Baclofen is available in different finished dosage forms depending on the intended route of administration and approved clinical use. Oral tablets and intrathecal formulations are distinct dosage forms with different formulation, manufacturing and quality requirements. Bulk Baclofen API should not be confused with the finished medicinal product.
Baclofen intended for pharmaceutical applications should be assessed against an appropriate pharmacopoeial monograph or approved product specification. Quality evaluation should establish the identity, purity, strength and consistency of the API.
Important quality attributes may include:
Analytical methods such as HPLC may be used for assay and related-substance testing, depending on the applicable pharmacopoeial procedure. Additional techniques may be used to confirm chemical identity and evaluate specific quality attributes.
Because Baclofen contains a stereogenic centre, its stereochemical identity should be considered where the applicable monograph or product specification requires it. The racemic API should not be confused with an individual enantiomer.
The final acceptance criteria should follow the current applicable BP, IP or USP monograph, where available, or an approved specification. Numerical limits should not be assumed from unrelated supplier specifications or research-grade product data.
Product documentation is essential for establishing the identity, quality and traceability of Baclofen API used in pharmaceutical development and manufacturing.
A Certificate of Analysis (COA) provides batch-specific analytical results and demonstrates whether the tested material complies with its stated specification. It should include relevant details such as appearance, identification, assay and related-substance results.
A Safety Data Sheet (SDS) provides information about safe handling, storage, potential hazards, exposure controls and emergency precautions.
Depending on the intended pharmaceutical application and applicable regulatory requirements, supporting documentation may include:
Documentation should clearly identify the Baclofen chemical form, CAS number, molecular formula, batch number, analytical methods and batch-specific test results.
Baclofen USP is baclofen intended to meet the applicable United States Pharmacopeia quality requirements.
The CAS Registry Number is 1134-47-0.
Its molecular formula is C₁₀H₁₂ClNO₂.
The molecular weight is 213.66 g/mol.
Baclofen is a centrally acting muscle relaxant and antispastic agent used in medicines for the management of muscle spasticity.
The cited USP monograph specifies 98.0%–102.0% baclofen, calculated on the anhydrous basis. Confirm the currently applicable monograph before publishing this as the product's release specification.
Baclofen is described in pharmaceutical product information as a white to off-white or creamy-white powder. Confirm the exact wording against the applicable specification.
Buyers can enquire about the applicable COA, SDS, product specification and other relevant technical documents, subject to availability.
Customers can contact Swapnroop Drugs & Pharmaceuticals with their required quantity, grade, destination market and documentation requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0%–102.0% |
| Loss on Drying | NMT 3.0% |
| Residue on Ignition | NMT 0.3% |
| Total Impurities | NMT 2.0% |